Want to see COO full AI Analyst Report?
COO Stock Chart & Stats
$70.31
$0.08(0.11%)
At close: 4:00 PM EDT
$70.31
$0.08(0.11%)
Day’s Range― - ―
52-Week Range$58.89 - $89.83
Previous Close$70.4
Volume1.47M
Average Volume (3M)2.58M
Market Cap
$14.85B
Enterprise Value$14.59K
Total Cash (Recent Filing)$138.80M
Total Debt (Recent Filing)$2.46B
Price to Earnings (P/E)64.6
Beta0.55
Next Earnings
Sep 09, 2026EPS Estimate
1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.18
Shares Outstanding195,030,620
10 Day Avg. Volume1,932,692
30 Day Avg. Volume2,578,923
Financial Highlights & Ratios
PEG Ratio-8.14
Price to Book (P/B)1.70
Price to Sales (P/S)3.42
P/FCF Ratio32.24
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$78.00Price Target Upside10.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)4.63
Revenue Forecast (FY)$4.31B
Bulls Say, Bears Say
Bulls Say
Global Contact-lens Leadership And Product MomentumA leading global position and continued adoption of daily lenses provide scale, brand strength and distribution advantages. MiSight growth adds a differentiated myopia-control opportunity that can support longer-term product mix and market expansion.
Sustained Revenue Growth With Reaffirmed GuidanceManagement's reaffirmed growth outlook indicates continued demand across contact lenses and fertility products. Consistent mid-single-digit expansion supports operating scale and suggests the core medical-products portfolio remains resilient over the planning period.
Solid Balance Sheet And Long-term Cash-generation TargetsModerate leverage and a large equity base provide financial flexibility for investment and potential capital returns. The multi-year free-cash-flow target also reflects management's expectation that current cash pressures can normalize as operational initiatives mature.
Bears Say
Recent Profitability And Cash-conversion DeteriorationLower margins and weaker free-cash-flow conversion reduce confidence in near-term earnings quality despite ongoing revenue growth. If sustained, the deterioration could limit reinvestment capacity and make future performance more dependent on operational recovery.
Material Fertility-business Litigation LiabilityThe settlement creates a substantial cash obligation and separates reported GAAP performance from adjusted results. Concentrated payments can constrain capital allocation, increase execution risk and reduce financial flexibility while the company resolves remaining claims.
Asia-Pacific Weakness And Ongoing Margin PressureWeakness in Japan and China, combined with product rationalization, may persist into 2027 and weigh on regional growth. FX, tariffs and lower production during inventory reduction add further pressure to margins and could delay operating leverage.
Cooper Co News
COO FAQ
What was Cooper Companies’s price range in the past 12 months?
Cooper Companies lowest stock price was $58.89 and its highest was $89.83 in the past 12 months.
What is Cooper Companies’s market cap?
Cooper Companies’s market cap is $14.85B.
When is Cooper Companies’s upcoming earnings report date?
Cooper Companies’s upcoming earnings report date is Sep 09, 2026 which is in 18 days.
How were Cooper Companies’s earnings last quarter?
Cooper Companies released its earnings results on Jun 04, 2026. The company reported $1.21 earnings per share for the quarter, beating the consensus estimate of $1.104 by $0.106.
Is Cooper Companies overvalued?
According to Wall Street analysts Cooper Companies’s price is currently Undervalued.
Does Cooper Companies pay dividends?
Cooper Companies pays a Semiannually dividend of $0.007 which represents an annual dividend yield of N/A. See more information on Cooper Companies dividends here
What is Cooper Companies’s EPS estimate?
Cooper Companies’s EPS estimate is 1.12.
How many shares outstanding does Cooper Companies have?
Cooper Companies has 195,030,620 shares outstanding.
What happened to Cooper Companies’s price movement after its last earnings report?
Cooper Companies reported an EPS of $1.21 in its last earnings report, beating expectations of $1.104. Following the earnings report the stock price went up 8.578%.
Which hedge fund is a major shareholder of Cooper Companies?
Currently, no hedge funds are holding shares in COO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cooper Co Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$78.00 (10.94% Upside)
$78.00 (10.94% Upside)
Blogger Sentiment
Neutral
COO Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 12.2%
Last 30 Days ▲ 12.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.55%
Trailing 12-Months
Company Description
Cooper Companies
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
COO Company Deck
COO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a generally positive operational and financial picture: record quarterly revenue and strong non-GAAP EPS, meaningful margin expansion, robust product-level growth (notably MiSight and CooperSurgical fertility), improved free cash flow and active strategic initiatives. However, material near-term headwinds create caution — a significant litigation settlement affecting GAAP results and concentrated cash outflows, Asia Pacific market softness tied to legacy product rationalization and consumer weakness (especially Japan/China), and expected short-term gross margin pressure from FX, tariffs and inventory optimization. Management balanced conservative guidance with a clear plan for capital allocation and strategic review progress, leaving the near-term outlook mixed but supported by strong execution and long-term cash-generation targets.View all COO earnings summariesCOO Net sales Breakdown
67.05% CooperVision
32.95% CooperSurgical
COO Stock 12 Month Forecast
Average Price Target
$78.00
▲(10.94% Upside)
Technical Analysis
Ownership Overview
0.60% Insiders
35.18% Mutual Funds
34.54% Other Institutional Investors
1.88% Public Companies and
Individual Investors